Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.

MLA

Edwards, Steve J., et al. “Axitinib, Cabozantinib, Everolimus, Nivolumab, Sunitinib and Best Supportive Care in Previously Treated Renal Cell Carcinoma: A Systematic Review and Economic Evaluation.” Health Technology Assessment (Winchester, England), vol. 22, no. 6, Jan. 2018, pp. 1–278. EBSCOhost, https://doi.org/10.3310/hta22060.

APA

Edwards, S. J., Wakefield, V., Cain, P., Karner, C., Kew, K., Bacelar, M., Masento, N., & Salih, F. (2018). Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England), 22(6), 1–278. https://doi.org/10.3310/hta22060

Chicago

Edwards, Steve J, Victoria Wakefield, Peter Cain, Charlotta Karner, Kayleigh Kew, Mariana Bacelar, Natalie Masento, and Fatima Salih. 2018. “Axitinib, Cabozantinib, Everolimus, Nivolumab, Sunitinib and Best Supportive Care in Previously Treated Renal Cell Carcinoma: A Systematic Review and Economic Evaluation.” Health Technology Assessment (Winchester, England) 22 (6): 1–278. doi:10.3310/hta22060.